Late-Breaking Science coming to ISC 2020

Be sure to hear the latest late-breaking science during the Thursday Main Event and the Friday Closing Main Event.

Thursday Main Event
10:30 a.m.-Noon
Hall K

  • Determining the Optimal Dose of Tenecteplase Before Endovascular Thrombectomy (EXTEND-IA TNK Part 2): A Multicenter, Randomized, Controlled Trial
  • ESCAPE-NA1 Trial
  • Multifocal Transcranial Rotating Permanent Magnet Stimulation in Chronic Ischemic Stroke
  • The Woven Study: Wingspan One-Year Vascular Imaging, Events and Neurologic Outcomes
  • Effects of Pre-Hospital Acute Stroke Treatment as Measured With the Modified Rankin Scale; the Berlin – Pre-Hospital Or Usual Care Delivery (B_PROUD) trial

Closing Main Event
10:30 a.m.-12:30 p.m.
Hall K

  • The Randomized Study of Endovascular Therapy With Versus Without Intravenous Tissue Plasminogen Activator in Acute Stroke With ICA and M1 Occlusion (SKIP Study)
  • Comparative Effectiveness of Home BP Telemonitoring Plus Nurse Case Management (HBPTM+NCM) Versus HBPTM Alone on Systolic BP (SBP) Reduction Among Minority Stroke Survivors
  • The Spot Sign and Tranexamic Acid on Preventing ICH Growth – Australasia Trial (STOP-AUST): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
  • Cilostazol Versus Other Anti-Platelet Drugs for the In-Stent Restenosis After Carotid Artery Stenting: The Carotid Artery Stenting With Cilostazol Addition for Restenosis (CAS-CARE) Trial
  • Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or PCI in Patients With Atrial Fibrillation and Prior Stroke: Insights From the AUGUSTUS Trial
  • World First Robotic Neurovascular Intervention Experience: Opening the Doors to Remote Procedures

    Register now for ISC 2020.